1 / 4

New Study provides Vaginal Atrophy Global Pipeline Overview and Therapeutic Landscape, H2 2016

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Vaginal Atrophy pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

markresearch
Download Presentation

New Study provides Vaginal Atrophy Global Pipeline Overview and Therapeutic Landscape, H2 2016

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Study provides Vaginal Atrophy Global Pipeline Overview and Therapeutic Landscape, H2 2016 N N N No o o o o o o of f f f P P P Pa a a ag g g ge e e es s s s – – 5 52 2 P P P Pu u u ub b b bl l l li i i is s s sh h h hi i i in n n ng g g g D D D Da a a at t t te e e e - - N No ov ve em mb be er r, , 2 20 01 16 6 B B B Br r r ro o o ow w w ws s s se e e e d d d de e e et t t ta a a ai i i il l l le e e ed d d d T T T TO O O OC C C C, , , , T T T Ta a a ab b b bl l l le e e es s s s, , , , F F F Fi i i ig g g gu u u ur r r re e e es s s s, , , , a a a an n n nd d d d C C C Ch h h ha a a ar r r rt t t ts s s s i i i in n n n G G G Gl l l lo o o ob b b ba a a al l l l S S S Se e e er r r ri i i ia a a al l l l D D D De e e ev v v vi i i ic c c ce e e e S S S Se e e er r r rv v v ve e e er r r r C C C Co o o on n n ns s s su u u um m m mp p p pt t t ti i i io o o on n n n 2 2 2 20 0 0 01 1 1 16 6 6 6 M M M Ma a a ar r r rk k k ke e e et t t t R R R Re e e es s s se e e ea a a ar r r rc c c ch h h h R R R Re e e ep p p po o o or r r rt t t t a a a at t t t: : : : http://www.marketresearchhub.com/report/vaginal-atrophy-atrophic-vaginitis-pipeline-review-h2-2016- report.html Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Vaginal Atrophy Vaginal Atrophy pipeline and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. pipeline guide guide helps in identifying and tracking emerging players in the market

  2. T T T Ta a a ab b b bl l l le e e e o o o of f f f C C C Co o o on n n nt t t te e e en n n nt t t ts s s s List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vaginal Atrophy (Atrophic Vaginitis) Overview 6 Therapeutics Development 7 Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 7 Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 8 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 12 Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 13 Allergan Plc 13 EndoCeutics, Inc. 14 Foamix Pharmaceuticals Ltd. 15 Ligand Pharmaceuticals, Inc. 16 Mithra Pharmaceuticals S.A. 17 PEPTONIC medical AB 18 Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Estetrol - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Estradiol hemihydrate - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 lasofoxifene tartrate - Drug Profile 32 Product Description 32 Mechanism Of Action 32 Request for Free Sample Report

  3. R&D Progress 32 oxytocin - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 prasterone - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 WC-3011 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 41 Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 42 Featured News & Press Releases 42 May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor 42 Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study 42 Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting 43 Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 44 Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting 45 Jul 17, 2015: Last subject exits Peptonic Medicals phase 2b VVA study 46 Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment 46 Mar 23, 2015: Peptonic Medicals formulation patent to be approved in the USA 47 Mar 18, 2015: Patient recruitment to Peptonic Medicals phase 2b study soon completed 47 Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin 48 Dec 01, 2014: Peptonic Medicals formulation patent to be approved in Europe 48 Oct 28, 2014: First patients included in Peptonic Medical ABs clinical phase 2b study 48 Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study 49 Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study 49 Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52 Request for Free Sample Report

  4. R R R Re e e ep p p po o o or r r rt t t t D D D De e e et t t ta a a ai i i il l l ls s s s – – D D D Da a a at t t te e e e o o o of f f f P P P Pu u u ub b b bl l l li i i is s s sh h h hi i i in n n ng g g g – – N No ov ve em mb be er r, , 2 20 01 16 6 N N N No o o o o o o of f f f P P P Pa a a ag g g ge e e es s s s – – 5 52 2 S S S Si i i in n n ng g g gl l l le e e e U U U Us s s se e e er r r r L L L Li i i ic c c ce e e en n n ns s s se e e e – – $ $2 20 00 00 0 M M M Mu u u ul l l lt t t ti i i ip p p pl l l le e e e U U U Us s s se e e er r r r L L L Li i i ic c c ce e e en n n ns s s se e e e – – $ $4 40 00 00 0 A A A Ab b b bo o o ou u u ut t t t M M M Ma a a ar r r rk k k ke e e et t t t R R R Re e e es s s se e e ea a a ar r r rc c c ch h h h H H H HU U U UB B B B : : : : M Ma ar rk ke et t R Re es se ea ar rc ch h H HU UB B i is s t th he e c cr re ed di ib bl le e s so ou ur rc ce e f fo or r g ga ai in ni in ng g t th he e m ma ar rk ke et t r re es se ea ar rc ch h r re ep po or rt ts s t th ha at t w wi il ll l e ex xp po on ne en nt ti ia al ll ly y a ac cc ce el le er ra at te e y yo ou ur r b bu us si in ne es ss s. . W l le ea ad di in ng g r re ep po or rt t r re es se el ll le er rs s i in n t th he e b bu us si in ne es ss s w wo or rl ld d c co om mm mi it tt te ed d t to ow wa ar rd ds s o op pt ti im mi iz zi in ng g y yo ou ur r b bu us si in ne es ss s. . T Th he e r re ep po or rt ts s w we e p pr ro ov vi id de e a ar re e b ba as se ed d o on n a a r re es se ea ar rc ch h t th ha at t c co ov ve er rs s a a m ma ag gn ni it tu ud de e o of f f fa ac ct to or rs s s su uc ch h a as s t te ec ch hn no ol lo og gi ic ca al l e ev vo ol lu ut ti io on n, , e ec co on no om mi ic c s sh hi if ft ts s a an nd d a a d de et ta ai il le ed d s st tu ud dy y o of f m ma ar rk ke et t s se eg gm me en nt ts s. . C C C Co o o on n n nt t t ta a a ac c c ct t t t– – – – 90 State Street, 90 State Street, Albany, NY 12207, Albany, NY 12207, United States United States Toll Free : 866 Toll Free : 866- -997 997- -4948 (US 4948 (US- -Canada) Canada) Tel : +1 Tel : +1- -518 518- -621 621- -2074 2074 Email : Email : mailto:sales@marketresearchhub.com mailto:sales@marketresearchhub.com Website : Website : http://www.marketresearchhub.com/ http://www.marketresearchhub.com/ Buy Report Now! We e a ar re e a am mo on ng g t th he e

More Related